| Ytd | -27.90% | |
| 1y | -6.46% |
| Open | 8.72 | Prev Close | 8.72 | Low | 8.71 | High | 9.36 | Mkt Cap | 698.53M |
| Vol | 39.36K | Avg Vol | 439.64K | EPS | -2.01 | P/E | -4.34 | Forward P/E | N/A |
| Beta | 0.39 | Short Ratio | 4.43 | Inst. Own | 52.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.17 | 200-d Avg | 10.27 | 1yr Est | 24.20 |
BBOT News
BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supporte
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a O
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.,
Top Wall Street analysts changed outlook on top names. For full rating changes, check analyst rating
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potent
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBO
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to s
BridgeBio Oncology Therapeutics is advancing differentiated KRAS inhibitors, targeting both active a
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally adv
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the O
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three cl
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
Pre-Market Stock Futures: Futures are trading higher after a stellar and surprising January jobs rep
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818
BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% obje
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation smal